Universal, off-the-shelf cell therapy

Allocetra™ is an innovative immunotherapy that is being developed to reprogram macrophages,
which were negatively reprogrammed by certain diseases out of their homeostatic state.

Healthy

allocetra

Mononuclear cells collected
from healthy donors

allocetra

Cells modification

allocetra

Modified through a proprietary
process to express “eat me”
signal (PtdSer) on their surface,
while maintaining an intact membrane

allocetra

Patient

allocetra

Triggering engulfment into
macrophages via binding to BAI,
TIM4, and stabilin 2, annexin V

allocetra Activated macrophage

allocetra Homeostatic macrophage

Clinical focus

Our clinical development programs focus on treating solid tumors, sepsis and COVID-19. Our most advanced product candidate, Allocetra™ has demonstrated positive safety, tolerability and efficacy in several clinical trials. In addition to our ongoing late-stage clinical trials in sepsis and COVID-19, we plan on initiating clinical trials of Allocetra™ in solid cancer patients during 2022.

Clinical experience
Extensive pre-clinical data
Clinical experience
Rich pipeline of registration studies targeting conditional marketing approval
Clinical experience
3 primary indications

Recent Publications